ArticleACS pharmacology & translational science2026
A Candidate Small Molecule Targeting Tachykinin Receptor 1 Suppresses Substance P‑Driven Extracellular Signal-Regulated Kinase Activation and Tumor Innervation in Pancreatic Cancer.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive tumor-nerve interactions that contribute to tumor progression, therapeutic resistance, and neural remodeling. Substance P (SP) and its receptor tachykinin receptor 1 (TACR1) have been implicated in cancer-associated neurogenic signaling, but pharmacological strategies to intercept this axis in PDAC remain insufficiently explored. Here, we identified TACR1 as a candidate druggable receptor expressed in pancreatic cancer cells and used structure-guided virtual screening of a mini-scaffold compound library to prioritize small molecules with predicted TACR1-binding potential. Among the top-ranked compounds, C547 showed TACR1 target engagement in cellular thermal shift assays and preferentially suppressed SP-induced growth and proliferation in TACR1-high MIA PaCa-2 cells, with limited effects in TACR1-low PANC-1 cells. C547 also attenuated SP-induced migration, reversed SP-associated reduction in gemcitabine sensitivity, and reduced the expression of epithelial-mesenchymal transition- and neurotrophin-associated genes. Mechanistically, SP increased ERK phosphorylation, whereas C547 reduced SP-driven ERK activation. Importantly, TACR1 knockdown diminished the inhibitory effects of C547 on cell growth and migration, supporting TACR1-dependent pharmacological activity. In an orthotopic KPPC pancreatic cancer model, C547 reduced tumor burden and decreased PGP9.5-positive tumor innervation without overt gross toxicity. These findings nominate the SP-TACR1-ERK axis as a pharmacologically targetable neuro-oncogenic pathway in PDAC and support C547 as a candidate TACR1-targeting lead compound for further optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.